HLB Life Science Co., Ltd. (KOSDAQ: 067630)

Market Cap	1.11T
Revenue (ttm)	92.87B
Net Income (ttm)	-9.20B
Shares Out	118.65M
EPS (ttm)	-87.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,772,008
Open	9,300.00
Previous Close	10,350.00
Day's Range	9,080.00 - 9,710.00
52-Week Range	7,700.00 - 25,000.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co...

• Industry: Cogeneration Services and Small Power Producers
• Founded: 1998
• Employees: 142
• Stock Exchange: KOSDAQ
• Ticker Symbol: 067630

Financial Performance

In 2023, HLB Life Science's revenue was 97.99 billion, a decrease of -1.61% compared to the previous year's 99.59 billion. Losses were -5.98 billion, -88.98% less than in 2022.